Effective Obesity Treatment: From Lifestyle to Innovative Drugs

Obesity: A Comprehensive Approach to Weight Loss

Obesity is a global health issue that requires a comprehensive and individualized approach to treatment. It significantly increases the risk of developing multiple comorbidities, such as type 2 diabetes, cardiovascular diseases, and obstructive sleep apnea [4]. Effective weight loss not only improves quality of life but also significantly reduces health risks. Modern obesity treatment strategies include lifestyle modification, pharmacotherapy, and, in some cases, surgical interventions.

The Foundation of Treatment: Lifestyle Modification

The cornerstone of any weight loss plan is lifestyle modification. Comprehensive interventions combining caloric restriction, increased physical activity, and behavioral changes demonstrate the highest efficacy, achieving a 5-10% weight loss at 6 months [6].

Clinicians are advised to use the "5As" counseling model (Assess, Advise, Agree, Assist, Arrange) in a patient-centered, non-judgmental manner to enhance patient motivation and adherence [6].

Key components of successful lifestyle modification include:

• **SMART goal setting:** specific, measurable, achievable, relevant, and time-bound [6].
• **Caloric deficit calculation:** an individualized approach to nutrition [6].
• **Self-monitoring:** regular tracking of progress [6].

Various dietary approaches can be effective and should be tailored to the patient's preferences [6]. At least 150 minutes of moderate-intensity physical activity per week or 75 minutes of high-intensity activity is recommended [6]. In some cases, referral to multidisciplinary programs or the use of digital/commercial solutions with personalized feedback may be recommended [6].

Obesity Pharmacotherapy: Modern Options

For many patients, lifestyle modifications may be insufficient to achieve and maintain meaningful weight loss. In such cases, pharmacotherapy becomes an important adjunct. Anti-obesity medications may be recommended for adults with a body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 in the presence of weight-related comorbidities [2, 4]. Pharmacotherapy is also used to maintain achieved weight loss and prevent weight regain [2].

Modern anti-obesity drugs include centrally acting agents, gastric lipase inhibitors, and incretin mimetics [4]. Drug selection must be strictly individualized, taking into account comorbidities (e.g., cardiovascular disease, obstructive sleep apnea), cost, and patient preferences [4].

Incretin Therapy: A Breakthrough in Obesity Treatment

Incretin therapy, utilizing glucagon-like peptide-1 (GLP-1) receptor agonists and dual receptor agonists, is a cornerstone of modern obesity management [1]. These agents promote weight loss by suppressing appetite, reducing caloric intake, and improving metabolic parameters [1].

Among the most studied and effective drugs in this group:

• **Liraglutide (3.0 mg daily):** promotes weight loss and can be used to prevent the development of type 2 diabetes in individuals with prediabetes and overweight or obesity [2].
• **Semaglutide (2.4 mg weekly):** has demonstrated substantial weight loss results beyond its glucose-lowering effect, shifting the obesity treatment paradigm toward pharmacological interventions [1].
• **Tirzepatide:** a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has shown the greatest weight loss benefits, achieving over 20% of initial body weight in some patients [4].

Other medications, such as the naltrexone/bupropion combination and orlistat, are also recommended for obesity management [2]. Orlistat, a gastric lipase inhibitor, can also be used for weight maintenance and the prevention of type 2 diabetes [2].

Individualized Approach and Special Patient Populations

The success of obesity treatment largely depends on an individualized approach. It is important to consider not only physiological but also psychological aspects. Unfortunately, individuals with obesity often face bias, which can affect the quality of medical care provided. For example, studies have shown that patients with obesity and type 2 diabetes were less likely to receive adequate treatment intensification for hypertension compared to normal-weight patients [5].

Obesity in children and adolescents: Pediatric obesity treatment also begins with lifestyle modification and behavioral therapy [3]. However, for adolescents (10-19 years) with obesity, pharmacotherapeutic options may also be considered, including GLP-1 receptor agonists, metformin, orlistat, or phentermine-topiramate, as well as combinations thereof [3].

Patients with end-stage renal disease (ESRD): Obesity is a major barrier to kidney transplantation, which significantly improves survival and quality of life. For such patients, adapted weight loss strategies are necessary, including lifestyle modification, pharmacotherapy (especially GLP-1 agonists), and bariatric surgery [8].

The Future of Obesity Treatment

The future of obesity management lies in optimizing combination therapies and developing new incretin-based molecules with dual or triple receptor activity [1]. These innovations promise even more effective and personalized approaches to combating obesity. Despite the growing body of evidence supporting the efficacy of pharmacotherapy, challenges remain regarding long-term efficacy, tolerability, and drug availability [1, 4].

References

1. Current clinical application of incretin therapy for obesity management. https://pubmed.ncbi.nlm.nih.gov/41420876/
2. Pharmacotherapy for obesity management. https://pubmed.ncbi.nlm.nih.gov/41378657/
3. Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/42329656/
4. Obesity Management: Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/42101582/
5. Hidden barriers: obesity bias in hypertension treatment. https://pubmed.ncbi.nlm.nih.gov/39160218/
6. Obesity Management: Lifestyle Interventions. https://pubmed.ncbi.nlm.nih.gov/42101581/
7. Overweight and obesity management. https://pubmed.ncbi.nlm.nih.gov/40029956/
8. Obesity Management in End-Stage Kidney Disease: Pathways to Improve Kidney Transplant Access. https://pubmed.ncbi.nlm.nih.gov/41905619/

Please note: The information provided in this article is for reference purposes only and cannot replace professional consultation, diagnosis, or treatment provided by a qualified medical specialist. Always consult a physician with any questions regarding your health or treatment.